Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

15.08
-0.1100-0.72%
Post-market: 15.100.0200+0.13%18:08 EDT
Volume:574.15K
Turnover:8.66M
Market Cap:776.51M
PE:7.32
High:15.25
Open:15.09
Low:14.86
Close:15.19
52wk High:21.03
52wk Low:7.90
Shares:51.49M
Float Shares:21.84M
Volume Ratio:0.73
T/O Rate:2.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.06
EPS(LYR):2.06
ROE:44.85%
ROA:-0.54%
PB:2.62
PE(LYR):7.32

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group

Reuters
·
Mar 04

Theravance Biopharma Plummets As Phase 3 Study Falls Short

Benzinga
·
Mar 04

Theravance Biopharma Is Maintained at Buy by BTIG

Dow Jones
·
Mar 04

Theravance Biopharma price target lowered to $21 from $40 at BTIG

TIPRANKS
·
Mar 04

BUZZ-U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy

Reuters
·
Mar 03

BUZZ-Theravance falls as co weighs options including possible sale after drug trial failure

Reuters
·
Mar 03

Theravance to Cut 50% of Workforce in Cost-Savings Push, Wind Down Late-Stage Program

Dow Jones
·
Mar 03

Theravance Biopharma falls 28% to $13.55 in pre-market trading

TIPRANKS
·
Mar 03

Theravance Biopharma implements cost reduction actions after study results

TIPRANKS
·
Mar 03

Theravance Biopharma Restructures After Ampreloxetine Trial Failure

TIPRANKS
·
Mar 03

Theravance Biopharma Shares Fall 28% Premarket After Blood Pressure Drug Does Not Meet Goal in Late-Stage Trial, Co Plans Strategic Review

THOMSON REUTERS
·
Mar 03

Theravance considers possible sale after drug trial setback

Reuters
·
Mar 03

Theravance Biopharma trading halted, news pending

TIPRANKS
·
Mar 03

BRIEF-Theravance Biopharma Reports Phase 3 Cypress Study Did Not Meet Primary Endpoint Board Accelerates Strategic Review And Announces Cost Reduction Actions

Reuters
·
Mar 03

Theravance Biopharma launches restructuring to cut costs by 60%

Reuters
·
Mar 03

Theravance Biopharma Inc: Strategic Review Committee Accelerating Ongoing Efforts to Evaluate Alternatives to Maximize Shareholder Value

THOMSON REUTERS
·
Mar 03

Theravance Biopharma Inc: Reduction Includes Complete Wind-Down of R&D Organization and a Decrease of Approximately 50% in G&a Employees

THOMSON REUTERS
·
Mar 03

Theravance Biopharma Inc: Restructuring Expected to Result in Company Generating Approximately $60 - $70 Mln of Annualized Cash Flow

THOMSON REUTERS
·
Mar 03

Theravance Biopharma Inc: Organizational Restructuring to Reduce Cost Base by Approximately 60%

THOMSON REUTERS
·
Mar 03

NASDAQ TRADE HALT HALT NEWS PENDING AT 08:26 AM

Reuters
·
Mar 03